Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.14) by 78.57 percent. This is a 47.06 percent decrease over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $71.553 million which beat the analyst consensus estimate of $65.886 million by 8.60 percent. This is a 21.53 percent increase over sales of $58.879 million the same period last year.